Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer

The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA approval of two PARP inhibitors for prostate cancer, HRD score analysis could help to refine treatment selection. We asse...

Full description

Saved in:
Bibliographic Details
Published inModern pathology Vol. 34; no. 6; pp. 1185 - 1193
Main Authors Lotan, Tamara L., Kaur, Harsimar B., Salles, Daniela C., Murali, Sanjana, Schaeffer, Edward M., Lanchbury, Jerry S., Isaacs, William B., Brown, Robert, Richardson, Andrea L., Cussenot, Olivier, Cancel-Tassin, Geraldine, Timms, Kirsten M., Antonarakis, Emmanuel S.
Format Journal Article
LanguageEnglish
Published New York Elsevier Inc 01.06.2021
Nature Publishing Group US
Elsevier Limited
Subjects
45
631/67/1857
631/67/589/466
Adult
Aged
Allelic Imbalance - genetics
Ataxia Telangiectasia Mutated Proteins - genetics
Biomarkers, Tumor - genetics
BRCA1 protein
BRCA2 protein
BRCA2 Protein - genetics
FDA approval
Genomic instability
Genomic Instability - genetics
Germ-Line Mutation - genetics
Heterozygosity
Homologous recombination
Humans
Laboratory Medicine
Loss of Heterozygosity - genetics
Male
Medicine
Medicine & Public Health
Middle Aged
Mutation
Ovarian cancer
Ovarian carcinoma
p53 Protein
Pathology
Poly(ADP-ribose) polymerase
Prostate cancer
Prostatic Neoplasms - genetics
Tumors
Online AccessGet full text
ISSN0893-3952
1530-0285
1530-0285
DOI10.1038/s41379-020-00731-4

Cover

Abstract The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA approval of two PARP inhibitors for prostate cancer, HRD score analysis could help to refine treatment selection. We assessed HRD score (defined as the sum of loss-of-heterozygosity, telomeric allelic imbalance, and large-scale state transitions) in three cohorts of primary prostate cancer, including a Johns Hopkins University (JHU) cohort with germline mutations in BRCA2, ATM, or CHEK2 (n = 64), the TCGA cohort (n = 391), and the PROGENE cohort (n = 102). In the JHU cohort, tumors with germline BRCA2 mutations had higher HRD scores (median = 27) than those with germline ATM or CHEK2 mutations (median = 16.5 [p = 0.029] and 9 [p < 0.001], respectively). For TCGA tumors without underlying HR pathway mutations, the median HRD score was 11, significantly lower than ovarian carcinoma lacking BRCA1/2 mutations (median = 28). In the absence of HR gene mutations, the median HRD score was unexpectedly higher among prostate cancers with TP53 mutations versus those without (17 vs. 11; p = 0.015); this finding was confirmed in the PROGENE cohort (24 vs. 16; p = 0.001). Finally, among eight BRCA2-altered patients who received olaparib, progression-free survival trended longer in those with HRD scores above versus below the median (14.9 vs. 9.9 months). We conclude that HRD scores are low in primary prostate cancer and higher in cases with germline BRCA2 or somatic TP53 mutations. Germline BRCA2-altered cases have significantly higher HRD scores than germline ATM-altered or CHEK2-altered cases, consistent with the lower efficacy of PARP inhibitors among the latter.
AbstractList The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA approval of two PARP inhibitors for prostate cancer, HRD score analysis could help to refine treatment selection. We assessed HRD score (defined as the sum of loss-of-heterozygosity, telomeric allelic imbalance, and large-scale state transitions) in three cohorts of primary prostate cancer, including a Johns Hopkins University (JHU) cohort with germline mutations in BRCA2 , ATM , or CHEK2 ( n  = 64), the TCGA cohort ( n  = 391), and the PROGENE cohort ( n  = 102). In the JHU cohort, tumors with germline BRCA2 mutations had higher HRD scores (median = 27) than those with germline ATM or CHEK2 mutations (median = 16.5 [ p  = 0.029] and 9 [ p  < 0.001], respectively). For TCGA tumors without underlying HR pathway mutations, the median HRD score was 11, significantly lower than ovarian carcinoma lacking BRCA1/2 mutations (median = 28). In the absence of HR gene mutations, the median HRD score was unexpectedly higher among prostate cancers with TP53 mutations versus those without (17 vs. 11; p  = 0.015); this finding was confirmed in the PROGENE cohort (24 vs. 16; p  = 0.001). Finally, among eight BRCA2 -altered patients who received olaparib, progression-free survival trended longer in those with HRD scores above versus below the median (14.9 vs. 9.9 months). We conclude that HRD scores are low in primary prostate cancer and higher in cases with germline BRCA2 or somatic TP53 mutations. Germline BRCA2 -altered cases have significantly higher HRD scores than germline ATM -altered or CHEK2 -altered cases, consistent with the lower efficacy of PARP inhibitors among the latter.
The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA approval of two PARP inhibitors for prostate cancer, HRD score analysis could help to refine treatment selection. We assessed HRD score (defined as the sum of loss-of-heterozygosity, telomeric allelic imbalance, and large-scale state transitions) in three cohorts of primary prostate cancer, including a Johns Hopkins University (JHU) cohort with germline mutations in BRCA2, ATM, or CHEK2 (n = 64), the TCGA cohort (n = 391), and the PROGENE cohort (n = 102). In the JHU cohort, tumors with germline BRCA2 mutations had higher HRD scores (median = 27) than those with germline ATM or CHEK2 mutations (median = 16.5 [p = 0.029] and 9 [p < 0.001], respectively). For TCGA tumors without underlying HR pathway mutations, the median HRD score was 11, significantly lower than ovarian carcinoma lacking BRCA1/2 mutations (median = 28). In the absence of HR gene mutations, the median HRD score was unexpectedly higher among prostate cancers with TP53 mutations versus those without (17 vs. 11; p = 0.015); this finding was confirmed in the PROGENE cohort (24 vs. 16; p = 0.001). Finally, among eight BRCA2-altered patients who received olaparib, progression-free survival trended longer in those with HRD scores above versus below the median (14.9 vs. 9.9 months). We conclude that HRD scores are low in primary prostate cancer and higher in cases with germline BRCA2 or somatic TP53 mutations. Germline BRCA2-altered cases have significantly higher HRD scores than germline ATM-altered or CHEK2-altered cases, consistent with the lower efficacy of PARP inhibitors among the latter.
The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA approval of two PARP inhibitors for prostate cancer, HRD score analysis could help to refine treatment selection. We assessed HRD score (defined as the sum of loss-of-heterozygosity, telomeric allelic imbalance, and large-scale state transitions) in three cohorts of primary prostate cancer, including a Johns Hopkins University (JHU) cohort with germline mutations in BRCA2, ATM, or CHEK2 (n = 64), the TCGA cohort (n = 391), and the PROGENE cohort (n = 102). In the JHU cohort, tumors with germline BRCA2 mutations had higher HRD scores (median = 27) than those with germline ATM or CHEK2 mutations (median = 16.5 [p = 0.029] and 9 [p < 0.001], respectively). For TCGA tumors without underlying HR pathway mutations, the median HRD score was 11, significantly lower than ovarian carcinoma lacking BRCA1/2 mutations (median = 28). In the absence of HR gene mutations, the median HRD score was unexpectedly higher among prostate cancers with TP53 mutations versus those without (17 vs. 11; p = 0.015); this finding was confirmed in the PROGENE cohort (24 vs. 16; p = 0.001). Finally, among eight BRCA2-altered patients who received olaparib, progression-free survival trended longer in those with HRD scores above versus below the median (14.9 vs. 9.9 months). We conclude that HRD scores are low in primary prostate cancer and higher in cases with germline BRCA2 or somatic TP53 mutations. Germline BRCA2-altered cases have significantly higher HRD scores than germline ATM-altered or CHEK2-altered cases, consistent with the lower efficacy of PARP inhibitors among the latter.The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA approval of two PARP inhibitors for prostate cancer, HRD score analysis could help to refine treatment selection. We assessed HRD score (defined as the sum of loss-of-heterozygosity, telomeric allelic imbalance, and large-scale state transitions) in three cohorts of primary prostate cancer, including a Johns Hopkins University (JHU) cohort with germline mutations in BRCA2, ATM, or CHEK2 (n = 64), the TCGA cohort (n = 391), and the PROGENE cohort (n = 102). In the JHU cohort, tumors with germline BRCA2 mutations had higher HRD scores (median = 27) than those with germline ATM or CHEK2 mutations (median = 16.5 [p = 0.029] and 9 [p < 0.001], respectively). For TCGA tumors without underlying HR pathway mutations, the median HRD score was 11, significantly lower than ovarian carcinoma lacking BRCA1/2 mutations (median = 28). In the absence of HR gene mutations, the median HRD score was unexpectedly higher among prostate cancers with TP53 mutations versus those without (17 vs. 11; p = 0.015); this finding was confirmed in the PROGENE cohort (24 vs. 16; p = 0.001). Finally, among eight BRCA2-altered patients who received olaparib, progression-free survival trended longer in those with HRD scores above versus below the median (14.9 vs. 9.9 months). We conclude that HRD scores are low in primary prostate cancer and higher in cases with germline BRCA2 or somatic TP53 mutations. Germline BRCA2-altered cases have significantly higher HRD scores than germline ATM-altered or CHEK2-altered cases, consistent with the lower efficacy of PARP inhibitors among the latter.
The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA-approval of two PARP inhibitors for prostate cancer, HRD score analysis could help to refine treatment selection. We assessed HRD score (defined as the sum of loss-of-heterozygosity, telomeric allelic imbalance, and large-scale state transitions) in three cohorts of primary prostate cancer, including a Johns Hopkins University (JHU) cohort with germline mutations in BRCA2 , ATM or CHEK2 (n=64), the TCGA cohort (n=391), and the PROGENE cohort (n=102). In the JHU cohort, tumors with germline BRCA2 mutations had higher HRD scores (median=27) than those with germline ATM or CHEK2 mutations (median=16.5 [p=0.029] and 9 [p<0.001], respectively). For TCGA tumors without underlying HR pathway mutations, the median HRD score was 11, significantly lower than ovarian carcinoma lacking BRCA1/2 mutations (median=28). In the absence of HR gene mutations, the median HRD score was unexpectedly higher among prostate cancers with TP53 mutations versus those without (17 vs 11; p=0.015); this finding was confirmed in the PROGENE cohort (24 vs 16; p=0.001). Finally, among eight BRCA2 -altered patients who received olaparib, progression-free survival trended longer in those with HRD scores above versus below the median (14.9 vs 9.9 months). We conclude that HRD scores are low in primary prostate cancer and higher in cases with germline BRCA2 or somatic TP53 mutations. Germline BRCA2 -altered cases have significantly higher HRD scores than germline ATM -altered or CHEK2 -altered cases, consistent with the lower efficacy of PARP inhibitors among the latter.
Author Antonarakis, Emmanuel S.
Brown, Robert
Lanchbury, Jerry S.
Lotan, Tamara L.
Salles, Daniela C.
Schaeffer, Edward M.
Cussenot, Olivier
Cancel-Tassin, Geraldine
Murali, Sanjana
Timms, Kirsten M.
Kaur, Harsimar B.
Richardson, Andrea L.
Isaacs, William B.
AuthorAffiliation 3 Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD
6 Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK
4 Department of Urology, Northwestern University, Chicago, IL
2 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
7 Department of Urology and Predictive Onco-Urology Group; APHP-Sorbonne University and CeRePP, Paris, France
1 Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD
5 Myriad Genetics, Salt Lake City, UT
AuthorAffiliation_xml – name: 7 Department of Urology and Predictive Onco-Urology Group; APHP-Sorbonne University and CeRePP, Paris, France
– name: 4 Department of Urology, Northwestern University, Chicago, IL
– name: 1 Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD
– name: 5 Myriad Genetics, Salt Lake City, UT
– name: 3 Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD
– name: 2 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
– name: 6 Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK
Author_xml – sequence: 1
  givenname: Tamara L.
  surname: Lotan
  fullname: Lotan, Tamara L.
  email: tlotan1@jhmi.edu
  organization: Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA
– sequence: 2
  givenname: Harsimar B.
  orcidid: 0000-0002-1178-7596
  surname: Kaur
  fullname: Kaur, Harsimar B.
  organization: Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA
– sequence: 3
  givenname: Daniela C.
  orcidid: 0000-0003-1904-185X
  surname: Salles
  fullname: Salles, Daniela C.
  organization: Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA
– sequence: 4
  givenname: Sanjana
  surname: Murali
  fullname: Murali, Sanjana
  organization: Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA
– sequence: 5
  givenname: Edward M.
  surname: Schaeffer
  fullname: Schaeffer, Edward M.
  organization: Department of Urology, Northwestern University, Chicago, IL, USA
– sequence: 6
  givenname: Jerry S.
  surname: Lanchbury
  fullname: Lanchbury, Jerry S.
  organization: Myriad Genetics, Salt Lake City, UT, USA
– sequence: 7
  givenname: William B.
  surname: Isaacs
  fullname: Isaacs, William B.
  organization: Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
– sequence: 8
  givenname: Robert
  surname: Brown
  fullname: Brown, Robert
  organization: Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK
– sequence: 9
  givenname: Andrea L.
  surname: Richardson
  fullname: Richardson, Andrea L.
  organization: Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA
– sequence: 10
  givenname: Olivier
  surname: Cussenot
  fullname: Cussenot, Olivier
  organization: Department of Urology and Predictive Onco-Urology Group, APHP-Sorbonne University, Paris, France
– sequence: 11
  givenname: Geraldine
  surname: Cancel-Tassin
  fullname: Cancel-Tassin, Geraldine
  organization: Department of Urology and Predictive Onco-Urology Group, APHP-Sorbonne University, Paris, France
– sequence: 12
  givenname: Kirsten M.
  surname: Timms
  fullname: Timms, Kirsten M.
  organization: Myriad Genetics, Salt Lake City, UT, USA
– sequence: 13
  givenname: Emmanuel S.
  orcidid: 0000-0003-0031-9655
  surname: Antonarakis
  fullname: Antonarakis, Emmanuel S.
  email: eantona1@jhmi.edu
  organization: Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33462368$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1r2zAUhsXoWNNsf2AXw7Cb9sKbvmxZMAZZ9pFBx6B010KWjzMVW8okJ9B_v9Ok3UcvciWM3-fl6Dw6IychBiDkJaNvGBXN2yyZULqknJaUKsFK-YTMWCXwkzfVCZnRRotS6IqfkrOcbyhlsmr4M3IqhKy5qJsZgVUc4xDXcZuLBC6OrQ928jEUHfTeeQjutjhfXX28KLKLCQofijWkcfABig9XywUvix2kjPji-ltphwkSdMUmxTzZCQpng4P0nDzt7ZDhxf05Jz8-f7persrL71--LheXpau0mMrG9gx0DRo6V6tOdK1T0FPmdM-5lgqcs0q2LZfAZN3RVjvNal11NfJN1Yg5eX_o3WzbEUsgTMkOZpP8aNOtidab__8E_9Os4840rJK1UFhwfl-Q4q8t5MmMPjsYBhsAV2S4VBpXryqB0dePojdxmwJez3B0oFTN8JyTV_9O9GeUBwMYaA4BhyvLCXrj_LQ3gAP6wTBq7mSbg2yDss1etpGI8kfoQ_tRSBygjOGAKv-OfZR6d6AA7e08Unn_NqDz-Gom00V_DP8NvA_PzQ
CitedBy_id crossref_primary_10_1002_pros_24788
crossref_primary_10_1016_j_jncc_2024_05_005
crossref_primary_10_3389_fmolb_2022_906922
crossref_primary_10_3390_cancers14122950
crossref_primary_10_3390_diagnostics13182962
crossref_primary_10_1097_MOU_0000000000001126
crossref_primary_10_1007_s00262_021_03050_y
crossref_primary_10_1002_2056_4538_70007
crossref_primary_10_1016_j_gim_2024_101243
crossref_primary_10_1002_pros_24195
crossref_primary_10_1093_jjco_hyae003
crossref_primary_10_3390_cancers14174157
crossref_primary_10_3390_ijms232113129
crossref_primary_10_1080_10408363_2023_2266482
crossref_primary_10_2147_OTT_S278092
crossref_primary_10_1172_jci_insight_152789
crossref_primary_10_3390_cancers17040682
crossref_primary_10_1097_CCO_0000000000000934
crossref_primary_10_1097_PAP_0000000000000422
crossref_primary_10_1007_s12325_024_02844_7
crossref_primary_10_1016_j_canlet_2021_11_021
crossref_primary_10_3390_genes13112039
crossref_primary_10_1186_s13000_023_01431_8
crossref_primary_10_21294_1814_4861_2025_24_1_59_69
crossref_primary_10_3390_cancers14030801
crossref_primary_10_1002_1878_0261_13411
crossref_primary_10_1002_pros_24461
crossref_primary_10_1158_1078_0432_CCR_21_1565
crossref_primary_10_3389_fimmu_2024_1210859
crossref_primary_10_1016_j_clgc_2024_02_003
crossref_primary_10_1007_s10549_022_06517_3
crossref_primary_10_3390_ijms25042184
crossref_primary_10_1093_oncolo_oyab053
crossref_primary_10_3390_cancers14163888
crossref_primary_10_1080_15384101_2023_2174339
crossref_primary_10_1111_bju_16120
crossref_primary_10_1016_j_path_2022_08_002
crossref_primary_10_1200_PO_23_00378
crossref_primary_10_2217_fon_2023_0550
crossref_primary_10_1200_PO_21_00152
crossref_primary_10_1186_s13053_021_00193_y
crossref_primary_10_1200_PO_22_00720
crossref_primary_10_1016_j_clgc_2023_12_011
crossref_primary_10_1016_j_eururo_2022_04_002
crossref_primary_10_1200_PO_23_00093
crossref_primary_10_1186_s12916_022_02430_0
crossref_primary_10_3233_BLC_211514
crossref_primary_10_1200_PO_22_00085
crossref_primary_10_1016_j_annonc_2021_11_013
crossref_primary_10_1158_2767_9764_CRC_23_0101
crossref_primary_10_1186_s40364_025_00740_y
crossref_primary_10_1186_s12885_022_10432_7
crossref_primary_10_1080_15384101_2023_2293594
crossref_primary_10_1200_JCO_23_02105
crossref_primary_10_1038_s41698_023_00402_y
crossref_primary_10_1080_14737140_2022_2081154
crossref_primary_10_1038_s41388_024_03148_4
crossref_primary_10_1038_s41698_023_00465_x
crossref_primary_10_1016_j_semcancer_2023_11_007
crossref_primary_10_17650_1726_9776_2023_19_2_75_88
crossref_primary_10_1200_PO_21_00141
crossref_primary_10_1038_s41435_023_00211_0
crossref_primary_10_1186_s12885_022_09669_z
crossref_primary_10_1007_s00432_023_05163_6
crossref_primary_10_1186_s13045_022_01360_x
crossref_primary_10_1186_s12967_022_03513_5
crossref_primary_10_1186_s40001_024_01936_y
crossref_primary_10_1186_s40364_024_00653_2
crossref_primary_10_5507_bp_2025_003
crossref_primary_10_3390_ijms25074094
Cites_doi 10.1016/j.eururo.2016.11.033
10.1016/j.cell.2015.10.025
10.1186/s13058-014-0475-x
10.1016/j.ccr.2011.04.010
10.1097/PAS.0b013e31821e8761
10.1158/1078-0432.CCR-20-0394
10.1056/NEJMc1913988
10.1200/JCO.20.01035
10.1158/1078-0432.CCR-15-2477
10.1073/pnas.0510441103
10.1002/pros.23042
10.1002/cncr.30808
10.1056/NEJMoa1506859
10.1200/JCO.20.02246
10.1038/s41416-018-0268-6
10.1158/1078-0432.CCR-19-2135
10.1001/jamaoncol.2018.6760
10.1200/PO.18.00283
10.1038/ng.3934
10.1016/j.eururo.2019.02.002
10.1002/humu.22478
10.1158/1541-7786.MCR-18-0034
10.1200/JCO.2017.75.7310
10.1080/14737140.2020.1781622
10.1056/NEJMoa1603144
10.1016/j.jmoldx.2016.10.002
10.1200/JCO.2019.37.7_suppl.202
10.1111/acel.12573
10.1158/1078-0432.CCR-16-2615
10.1158/1078-0432.CCR-20-0764
10.1182/blood.V98.3.814
10.1186/s13059-019-1867-0
10.1158/1078-0432.CCR-17-0955
10.1097/CCO.0000000000000617
10.1038/ncomms4156
10.1007/s00345-018-2290-y
10.1038/nature03445
10.1200/JCO.2020.38.6_suppl.119
10.1056/NEJMoa1911440
10.1093/jnci/djy028
10.1200/PO.19.00081
10.1016/S1470-2045(14)71021-6
10.1038/nrm2858
10.1200/JCO.2019.37.15_suppl.5045
10.1158/1078-0432.CCR-19-1587
10.1038/s41586-019-1382-1
ContentType Journal Article
Copyright 2021 United States & Canadian Academy of Pathology
The Author(s), under exclusive licence to United States & Canadian Academy of Pathology 2021
The Author(s), under exclusive licence to United States & Canadian Academy of Pathology 2021.
Copyright_xml – notice: 2021 United States & Canadian Academy of Pathology
– notice: The Author(s), under exclusive licence to United States & Canadian Academy of Pathology 2021
– notice: The Author(s), under exclusive licence to United States & Canadian Academy of Pathology 2021.
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QP
7RV
7TK
7X7
7XB
88A
88E
8AO
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB0
LK8
M0S
M1P
M7P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1038/s41379-020-00731-4
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Nursing & Allied Health Database
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
ProQuest Central Student
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1530-0285
EndPage 1193
ExternalDocumentID PMC8154637
33462368
10_1038_s41379_020_00731_4
S089339522200607X
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
  grantid: 5P30 CA006973
  funderid: https://doi.org/10.13039/100000054
– fundername: U.S. Department of Health & Human Services | National Institutes of Health (NIH)
  grantid: P50 CA58236
  funderid: https://doi.org/10.13039/100000002
– fundername: Cancer Research UK
  grantid: 13086
– fundername: NCI NIH HHS
  grantid: P50 CA058236
– fundername: NCI NIH HHS
  grantid: P30 CA006973
GroupedDBID ---
-Q-
.GJ
0R~
123
29M
2WC
36B
39C
3V.
4.4
53G
5RE
6I.
70F
7RV
7X7
88A
88E
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
AADWK
AAFTH
AANZL
AAQQT
AASDW
AAWBL
AAWTL
AAXUO
AAYFA
AAYJO
AAZLF
ABAWZ
ABGIJ
ABJNI
ABLJU
ABUWG
ACBMV
ACBRV
ACBYP
ACGFO
ACGFS
ACIGE
ACKTT
ACPRK
ACRQY
ACTTH
ACVWB
ACZOJ
ADBBV
ADFRT
ADHDB
ADMDM
ADQMX
ADYYL
AEDAW
AEFTE
AEJRE
AENEX
AEXYK
AFKRA
AFOSN
AFSHS
AGAYW
AGEZK
AGGBP
AGHAI
AHGBK
AHMBA
AHSBF
AILAN
AJDOV
AJRNO
ALFFA
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AMRJV
AMYLF
AXYYD
BAWUL
BBNVY
BENPR
BHPHI
BKEYQ
BKKNO
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
DIK
DNIVK
DU5
E3Z
EBLON
EBS
EE.
EIOEI
EJD
EX3
F5P
FDB
FDQFY
FERAY
FIZPM
FSGXE
FYUFA
GX1
HCIFZ
HMCUK
HZ~
IWAJR
JSO
JZLTJ
KQ8
LK8
M0L
M1P
M7P
NAO
NAPCQ
NQJWS
NYICJ
O9-
OK1
OWW
P2P
PQQKQ
PROAC
PSQYO
Q2X
RNS
RNT
RNTTT
ROL
SNX
SNYQT
SOHCF
SRMVM
SWTZT
TAOOD
TBHMF
TDRGL
TR2
TSG
UKHRP
WOW
YFH
ZA5
ZGI
ZXP
AALRI
ADVLN
AFJKZ
AITUG
AKRWK
ALIPV
AAYWO
AAYXX
ACVFH
ADCNI
AEUPX
AFPUW
AGCQF
AIGII
AKBMS
AKYEP
APXCP
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EFKBS
EIF
NPM
PJZUB
PPXIY
PQGLB
7QP
7TK
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c593t-8af1e96e9edc67d3dbc7ef01c9f22947ecca74bb24e146d0b9c91695d6c598583
IEDL.DBID 7X7
ISSN 0893-3952
1530-0285
IngestDate Thu Aug 21 18:30:46 EDT 2025
Sun Sep 28 06:00:38 EDT 2025
Fri Jul 25 19:29:19 EDT 2025
Mon Jul 21 05:35:25 EDT 2025
Tue Jul 01 02:26:43 EDT 2025
Thu Apr 24 22:53:18 EDT 2025
Fri Feb 21 02:38:33 EST 2025
Fri Feb 23 02:38:30 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License This article is made available under the Elsevier license.
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c593t-8af1e96e9edc67d3dbc7ef01c9f22947ecca74bb24e146d0b9c91695d6c598583
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-1904-185X
0000-0003-0031-9655
0000-0002-1178-7596
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8154637
PMID 33462368
PQID 2530776125
PQPubID 33743
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8154637
proquest_miscellaneous_2479038753
proquest_journals_2530776125
pubmed_primary_33462368
crossref_citationtrail_10_1038_s41379_020_00731_4
crossref_primary_10_1038_s41379_020_00731_4
springer_journals_10_1038_s41379_020_00731_4
elsevier_sciencedirect_doi_10_1038_s41379_020_00731_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-06-01
PublicationDateYYYYMMDD 2021-06-01
PublicationDate_xml – month: 06
  year: 2021
  text: 2021-06-01
  day: 01
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: United States
– name: Kidlington
PublicationSubtitle Publishing innovative clinical and translational research in the pathology of human disease
PublicationTitle Modern pathology
PublicationTitleAbbrev Mod Pathol
PublicationTitleAlternate Mod Pathol
PublicationYear 2021
Publisher Elsevier Inc
Nature Publishing Group US
Elsevier Limited
Publisher_xml – name: Elsevier Inc
– name: Nature Publishing Group US
– name: Elsevier Limited
References Bono JSD, Mehra N, Higano CS, Saad F, Buttigliero C, Mata M, et al. TALAPRO-1: a phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA). J Clin Oncol. 2020;38.
Brenner, Ateeq, Li, Yocum, Cao, Asangani (bib28) 2011; 19
de Bono, Mateo, Fizazi, Saad, Shore, Sandhu (bib3) 2020; 382
Guedes, Antonarakis, Schweizer, Mirkheshti, Almutairi, Park (bib26) 2017; 23
Lheureux, Lai, Dougherty, Runswick, Hodgson, Timms (bib40) 2017; 23
Cancer Genome Atlas Research N. (bib17) 2015; 163
Marshall, Antonarakis (bib13) 2020; 32
Kaur, Salles, Murali, Hicks, Nguyen, Pritchard (bib16) 2020; 26
Na, Zheng, Han, Yu, Jiang, Shah (bib14) 2017; 71
Timms, Abkevich, Hughes, Neff, Reid, Morris (bib21) 2014; 16
Abida, Campbell, Patnaik, Shapiro, Sautois, Vogelzang (bib4) 2020; 26
Lalonde, Ishkanian, Sykes, Fraser, Ross-Adams, Erho (bib27) 2014; 15
Pettitt, Sherrington, Stewart, Cawley, Taylor, Stankovic (bib45) 2001; 98
Patel, Braicu, Timms, Solimeno, Tshiaba, Reid (bib20) 2018; 119
Poti, Gyergyak, Nemeth, Rusz, Toth, Kovacshazi (bib34) 2019; 20
Smith MR, Sandhu SK, Kelly WK, Scher HI, Efstathiou E, Lara P, et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. J Clin Oncol. 2019;37.
Antonarakis ES, Wang H, Teply BA, Kelly WK, Willms J, Sullivan R, et al. Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis. J Clin Oncol. 2019;37.
Abida, Patnaik, Campbell, Shapiro, Bryce, McDermott (bib7) 2020; 38
Chaux, Albadine, Toubaji, Hicks, Meeker, Platz (bib24) 2011; 35
Jonsson, Bandlamudi, Cheng, Srinivasan, Chavan, Friedman (bib31) 2019; 571
Mateo, Carreira, Sandhu, Miranda, Mossop, Perez-Lopez (bib2) 2015; 373
Stronach, Paul, Timms, Hughes, Brown, Neff (bib19) 2018; 16
Greiner, Dasgupta, Ho, Weisenburger, Smith, Lynch (bib44) 2006; 103
Farmer, McCabe, Lord, Tutt, Johnson, Richardson (bib46) 2005; 434
Velho PI, Lim D, Wang H, Park JC, Kaur HB, Almutairi F, et al. Molecular characterization and clinical outcomes of primary gleason pattern 5 prostate cancer after radical prostatectomy. JCO Precis Oncol. 2019;3.
Quigley, Dang, Zhao, Lloyd, Aggarwal, Alumkal (bib39) 2018; 174
Markowski, Antonarakis (bib47) 2020; 20
Negrini, Gorgoulis, Halazonetis (bib43) 2010; 11
Guidugli, Carreira, Caputo, Ehlen, Galli, Monteiro (bib37) 2014; 35
Hussain, Daignault-Newton, Twardowski, Albany, Stein, Kunju (bib29) 2018; 36
.
Morais, Herawi, Toubaji, Albadine, Hicks, Netto (bib23) 2015; 75
Markowski, Antonarakis (bib41) 2020; 38
Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis Oncol. 2019;3.
Telli, Timms, Reid, Hennessy, Mills, Jensen (bib10) 2016; 22
Galbiati, Beausejour, d'Adda, di Fagagna (bib36) 2017; 16
Weigelt, Bi, Kumar, Blecua, Mandelker, Geyer (bib42) 2018; 110
Nicolosi, Ledet, Yang, Michalski, Freschi, O'Leary (bib12) 2019; 5
Kanchi, Johnson, Lu, McLellan, Leiserson, Wendl (bib25) 2014; 5
Spratt, Alshalalfa, Fishbane, Weiner, Mehra, Mahal (bib30) 2019; 25
Marshall, Sokolova, McNatty, Cheng, Eisenberger, Bryce (bib8) 2019; 76
Li, Datto, Duncavage, Kulkarni, Lindeman, Roy (bib22) 2017; 19
Hughley, Karlic, Joshi, Turnbull, Foulkes, Polak (bib33) 2020; 383
Sztupinszki, Diossy, Krzystanek, Borcsok, Pomerantz, Tisza (bib35) 2020; 26
Pritchard, Mateo, Walsh, De Sarkar, Abida, Beltran (bib11) 2016; 375
Leon, Cancel-Tassin, Drouin, Audouin, Varinot, Comperat (bib18) 2018; 36
Polak, Kim, Braunstein, Karlic, Haradhavala, Tiao (bib32) 2017; 49
Pomerantz, Spisak, Jia, Cronin, Csabai, Ledet (bib38) 2017; 123
GalbiatiABeausejourCd’Addadi FagagnaFA novel single-cell method provides direct evidence of persistent DNA damage in senescent cells and aged mammalian tissuesAging Cell20171642271:CAS:528:DC%2BC2sXhs1WgsLY%3D28124509533454210.1111/acel.12573
NegriniSGorgoulisVGHalazonetisTDGenomic instability—an evolving hallmark of cancerNat Rev Mol Cell Biol20101122081:CAS:528:DC%2BC3cXitlaisb4%3D2017739710.1038/nrm2858
TimmsKMAbkevichVHughesENeffCReidJMorrisBAssociation of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypesBreast Cancer Res2014164758325475740430891010.1186/s13058-014-0475-x
NaRZhengSLHanMYuHJiangDShahSGermline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at deathEur Urol20177174071:CAS:528:DC%2BC28XhvF2mtLnO2798935410.1016/j.eururo.2016.11.033
GreinerTCDasguptaCHoVVWeisenburgerDDSmithLMLynchJCMutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphomaProc Natl Acad Sci USA2006103235271:CAS:528:DC%2BD28XhslGjt7w%3D16461462141371610.1073/pnas.0510441103
Smith MR, Sandhu SK, Kelly WK, Scher HI, Efstathiou E, Lara P, et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. J Clin Oncol. 2019;37. https://doi.org/10.1200/JCO.2019.37.7_suppl.202.
Cancer Genome Atlas Research N.The molecular taxonomy of primary prostate cancerCell201516310112510.1016/j.cell.2015.10.025
GuidugliLCarreiraACaputoSMEhlenAGalliAMonteiroANFunctional assays for analysis of variants of uncertain significance in BRCA2Hum Mutat201435151641:CAS:528:DC%2BC2cXotFWmtg%3D%3D2432393810.1002/humu.22478
MarshallCHSokolovaAOMcNattyALChengHHEisenbergerMABryceAHDifferential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutationsEur Urol20197645281:CAS:528:DC%2BC1MXjtVWitr4%3D30797618670397410.1016/j.eururo.2019.02.002
PatelJNBraicuITimmsKMSolimenoCTshiabaPReidJCharacterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancerBr J Cancer2018119106061:CAS:528:DC%2BC1cXhvFChtrjM30318511621947610.1038/s41416-018-0268-6
BrennerJCAteeqBLiYYocumAKCaoQAsanganiIAMechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancerCancer Cell201119664781:CAS:528:DC%2BC3MXmtFGlsL4%3D21575865311347310.1016/j.ccr.2011.04.010
SztupinszkiZDiossyMKrzystanekMBorcsokJPomerantzMMTiszaVDetection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutationsClin Cancer Res2020262673801:CAS:528:DC%2BB3cXitVKrt7jK32071115838708610.1158/1078-0432.CCR-19-2135
HussainMDaignault-NewtonSTwardowskiPWAlbanyCSteinMNKunjuLPTargeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012J Clin Oncol20183699191:CAS:528:DC%2BC1cXit1amtr3E2926143910.1200/JCO.2017.75.7310
QuigleyDADangHXZhaoSGLloydPAggarwalRAlumkalJJGenomic hallmarks and structural variation in metastatic prostateCancer Cell2018174758691:CAS:528:DC%2BC1cXhtlGltb%2FE
PomerantzMMSpisakSJiaLCroninAMCsabaiILedetEThe association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancerCancer2017123353291:CAS:528:DC%2BC2sXhsVGhsrnF2860893110.1002/cncr.30808
Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis Oncol. 2019;3. https://doi.org/10.1200/PO.18.00283.
Velho PI, Lim D, Wang H, Park JC, Kaur HB, Almutairi F, et al. Molecular characterization and clinical outcomes of primary gleason pattern 5 prostate cancer after radical prostatectomy. JCO Precis Oncol. 2019;3. https://doi.org/10.1200/PO.19.00081.
MoraisCLHerawiMToubajiAAlbadineRHicksJNettoGJPTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomasProstate201575161091:CAS:528:DC%2BC2MXhtlelsL7E26178158453735010.1002/pros.23042
ChauxAAlbadineRToubajiAHicksJMeekerAPlatzEAImmunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomasAm J Surg Pathol20113510142021677539350567610.1097/PAS.0b013e31821e8761
MarkowskiMCAntonarakisESBRCA1 versus BRCA2 and PARP inhibitor sensitivity in prostate cancer: more different than alike?J Clin Oncol2020383735932870734765501810.1200/JCO.20.02246
GuedesLBAntonarakisESSchweizerMTMirkheshtiNAlmutairiFParkJCMSH2 loss in primary prostate cancerClin Cancer Res2017236863741:CAS:528:DC%2BC2sXhvVSnurfM28790115569083410.1158/1078-0432.CCR-17-0955
Antonarakis ES, Wang H, Teply BA, Kelly WK, Willms J, Sullivan R, et al. Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis. J Clin Oncol. 2019;37. https://doi.org/10.1200/JCO.2019.37.15_suppl.5045.
WeigeltBBiRKumarRBlecuaPMandelkerDLGeyerFCThe landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriersJ Natl Cancer Inst20181101030429506079613692510.1093/jnci/djy028
NicolosiPLedetEYangSMichalskiSFreschiBO’LearyEPrevalence of germline variants in prostate cancer and implications for current genetic testing guidelinesJAMA Oncol20195523830730552645911210.1001/jamaoncol.2018.6760
AbidaWCampbellDPatnaikAShapiroJDSautoisBVogelzangNJNon-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 studyClin Cancer Res2020262487961:CAS:528:DC%2BB3cXitVOgtbvO32086346843535410.1158/1078-0432.CCR-20-0394
MateoJCarreiraSSandhuSMirandaSMossopHPerez-LopezRDNA-repair defects and olaparib in metastatic prostate cancerN Engl J Med201537316977081:CAS:528:DC%2BC28XksVemuro%3D26510020522859510.1056/NEJMoa1506859
LeonPCancel-TassinGDrouinSAudouinMVarinotJComperatEComparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomyWorld J Urol20183614955001:CAS:528:DC%2BC1cXosFCnsrs%3D2967914010.1007/s00345-018-2290-y
LiMMDattoMDuncavageEJKulkarniSLindemanNIRoySStandards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American PathologistsJ Mol Diagn2017194231:CAS:528:DC%2BC28XitFWls7jM27993330570719610.1016/j.jmoldx.2016.10.002
LheureuxSLaiZDoughertyBARunswickSHodgsonDRTimmsKMLong-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterizationClin Cancer Res2017234086941:CAS:528:DC%2BC2sXht1Ghu7fJ2822327410.1158/1078-0432.CCR-16-2615
PritchardCCMateoJWalshMFDe SarkarNAbidaWBeltranHInherited DNA-repair gene mutations in men with metastatic prostate cancerN Engl J Med2016375443531:CAS:528:DC%2BC28XhvF2ks7%2FN27433846498661610.1056/NEJMoa1603144
MarkowskiMCAntonarakisESPARP inhibitors in prostate cancer: time to narrow patient selection?Expert Rev Anticancer Ther20202052361:CAS:528:DC%2BB3cXhsVyjsr%2FN3252117810.1080/14737140.2020.1781622
KaurHSallesDCMuraliSHicksJLNguyenMPritchardCCGenomic and clinical-pathologic characterization of ATM-deficient prostate cancerClin Cancer Res2020264869811:CAS:528:DC%2BB3cXisFSrtr%2FP32694154750114910.1158/1078-0432.CCR-20-0764
JonssonPBandlamudiCChengMLSrinivasanPChavanSSFriedmanNDTumour lineage shapes BRCA-mediated phenotypesNature201957157691:CAS:528:DC%2BC1MXhsVeqs7rN31292550704823910.1038/s41586-019-1382-1
MarshallCHAntonarakisESTherapeutic targeting of the DNA damage response in prostate cancerCurr Opin Oncol202032216221:CAS:528:DC%2BB3cXmtl2lsLw%3D32168038814765710.1097/CCO.0000000000000617
SprattDEAlshalalfaMFishbaneNWeinerABMehraRMahalBATranscriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment naive primary prostate cancerClin Cancer Res2019256721301:CAS:528:DC%2BB3cXhslWitL7F31515456685896410.1158/1078-0432.CCR-19-1587
FarmerHMcCabeNLordCJTuttANJohnsonDARichardsonTBTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434917211:CAS:528:DC%2BD2MXjtFOmsrc%3D1582996710.1038/nature03445
PettittARSherringtonPDStewartGCawleyJCTaylorAMStankovicTp53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutationBlood200198814221:CAS:528:DC%2BD3MXlsFKru7s%3D1146818310.1182/blood.V98.3.814
KanchiKLJohnsonKJLuCMcLellanMDLeisersonMDWendlMCIntegrated analysis of germline and somatic variants in ovarian cancerNat Commun201452444849910.1038/ncomms4156
StronachEAPaulJTimmsKMHughesEBrownKNeffCBiomarker assessment of HR deficiency, tumor BRCA1/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapyMol Cancer Res2018161103111:CAS:528:DC%2BC1cXht1alu77P2972481510.1158/1541-7786.MCR-18-0034
de BonoJMateoJFizaziKSaadFShoreNSandhuSOlaparib for metastatic castration-resistant prostate cancerN Engl J Med202038220911023234389010.1056/NEJMoa1911440
HughleyRKarlicRJoshiHTurnbullCFoulkesWDPolakPEtiologic index: a case-only measure of BRCA1/2-associated cancer riskN Engl J Med2020383286832668122754637010.1056/NEJMc1913988
LalondeEIshkanianASSykesJFraserMRoss-AdamsHErhoNTumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort studyLancet Oncol2014151521322545637110.1016/S1470-2045(14)71021-6
TelliMLTimmsKMReidJHennessyBMillsGBJensenKCHomologous recombination deficiency (HRD) score predicts
Pritchard (10.1038/s41379-020-00731-4_bib11) 2016; 375
Guedes (10.1038/s41379-020-00731-4_bib26) 2017; 23
Lalonde (10.1038/s41379-020-00731-4_bib27) 2014; 15
Hussain (10.1038/s41379-020-00731-4_bib29) 2018; 36
Markowski (10.1038/s41379-020-00731-4_bib47) 2020; 20
Abida (10.1038/s41379-020-00731-4_bib7) 2020; 38
Spratt (10.1038/s41379-020-00731-4_bib30) 2019; 25
de Bono (10.1038/s41379-020-00731-4_bib3) 2020; 382
Telli (10.1038/s41379-020-00731-4_bib10) 2016; 22
Li (10.1038/s41379-020-00731-4_bib22) 2017; 19
Quigley (10.1038/s41379-020-00731-4_bib39) 2018; 174
Nicolosi (10.1038/s41379-020-00731-4_bib12) 2019; 5
Jonsson (10.1038/s41379-020-00731-4_bib31) 2019; 571
10.1038/s41379-020-00731-4_bib15
Kaur (10.1038/s41379-020-00731-4_bib16) 2020; 26
Guidugli (10.1038/s41379-020-00731-4_bib37) 2014; 35
Abida (10.1038/s41379-020-00731-4_bib4) 2020; 26
Markowski (10.1038/s41379-020-00731-4_bib41) 2020; 38
Pomerantz (10.1038/s41379-020-00731-4_bib38) 2017; 123
Kanchi (10.1038/s41379-020-00731-4_bib25) 2014; 5
Stronach (10.1038/s41379-020-00731-4_bib19) 2018; 16
Marshall (10.1038/s41379-020-00731-4_bib13) 2020; 32
Weigelt (10.1038/s41379-020-00731-4_bib42) 2018; 110
Marshall (10.1038/s41379-020-00731-4_bib8) 2019; 76
Hughley (10.1038/s41379-020-00731-4_bib33) 2020; 383
Pettitt (10.1038/s41379-020-00731-4_bib45) 2001; 98
Lheureux (10.1038/s41379-020-00731-4_bib40) 2017; 23
Cancer Genome Atlas Research N. (10.1038/s41379-020-00731-4_bib17) 2015; 163
Patel (10.1038/s41379-020-00731-4_bib20) 2018; 119
Chaux (10.1038/s41379-020-00731-4_bib24) 2011; 35
Greiner (10.1038/s41379-020-00731-4_bib44) 2006; 103
Timms (10.1038/s41379-020-00731-4_bib21) 2014; 16
Morais (10.1038/s41379-020-00731-4_bib23) 2015; 75
Brenner (10.1038/s41379-020-00731-4_bib28) 2011; 19
Galbiati (10.1038/s41379-020-00731-4_bib36) 2017; 16
Polak (10.1038/s41379-020-00731-4_bib32) 2017; 49
Negrini (10.1038/s41379-020-00731-4_bib43) 2010; 11
Poti (10.1038/s41379-020-00731-4_bib34) 2019; 20
Farmer (10.1038/s41379-020-00731-4_bib46) 2005; 434
10.1038/s41379-020-00731-4_bib1
10.1038/s41379-020-00731-4_bib5
10.1038/s41379-020-00731-4_bib6
10.1038/s41379-020-00731-4_bib9
Na (10.1038/s41379-020-00731-4_bib14) 2017; 71
Leon (10.1038/s41379-020-00731-4_bib18) 2018; 36
Mateo (10.1038/s41379-020-00731-4_bib2) 2015; 373
Sztupinszki (10.1038/s41379-020-00731-4_bib35) 2020; 26
References_xml – volume: 5
  year: 2014
  ident: bib25
  article-title: Integrated analysis of germline and somatic variants in ovarian cancer
  publication-title: Nat Commun
– reference: Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis Oncol. 2019;3.
– volume: 123
  start-page: 3532
  year: 2017
  end-page: 3539
  ident: bib38
  article-title: The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer
  publication-title: Cancer
– volume: 23
  start-page: 4086
  year: 2017
  end-page: 4094
  ident: bib40
  article-title: Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization
  publication-title: Clin Cancer Res
– volume: 5
  start-page: 523
  year: 2019
  end-page: 528
  ident: bib12
  article-title: Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines
  publication-title: JAMA Oncol
– volume: 571
  start-page: 576
  year: 2019
  end-page: 579
  ident: bib31
  article-title: Tumour lineage shapes BRCA-mediated phenotypes
  publication-title: Nature
– volume: 22
  start-page: 3764
  year: 2016
  end-page: 3773
  ident: bib10
  article-title: Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer
  publication-title: Clin Cancer Res
– volume: 35
  start-page: 151
  year: 2014
  end-page: 164
  ident: bib37
  article-title: Functional assays for analysis of variants of uncertain significance in BRCA2
  publication-title: Hum Mutat
– volume: 163
  start-page: 1011
  year: 2015
  end-page: 1025
  ident: bib17
  article-title: The molecular taxonomy of primary prostate cancer
  publication-title: Cell
– volume: 76
  start-page: 452
  year: 2019
  end-page: 458
  ident: bib8
  article-title: Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations
  publication-title: Eur Urol
– volume: 75
  start-page: 1610
  year: 2015
  end-page: 1619
  ident: bib23
  article-title: PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas
  publication-title: Prostate
– volume: 49
  start-page: 1476
  year: 2017
  end-page: 1486
  ident: bib32
  article-title: A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
  publication-title: Nat Genet
– volume: 15
  start-page: 1521
  year: 2014
  end-page: 1532
  ident: bib27
  article-title: Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
  publication-title: Lancet Oncol
– volume: 36
  start-page: 1495
  year: 2018
  end-page: 1500
  ident: bib18
  article-title: Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy
  publication-title: World J Urol
– volume: 20
  start-page: 523
  year: 2020
  end-page: 526
  ident: bib47
  article-title: PARP inhibitors in prostate cancer: time to narrow patient selection?
  publication-title: Expert Rev Anticancer Ther
– volume: 383
  start-page: 286
  year: 2020
  end-page: 288
  ident: bib33
  article-title: Etiologic index: a case-only measure of BRCA1/2-associated cancer risk
  publication-title: N Engl J Med
– reference: Velho PI, Lim D, Wang H, Park JC, Kaur HB, Almutairi F, et al. Molecular characterization and clinical outcomes of primary gleason pattern 5 prostate cancer after radical prostatectomy. JCO Precis Oncol. 2019;3.
– volume: 373
  start-page: 1697
  year: 2015
  end-page: 1708
  ident: bib2
  article-title: DNA-repair defects and olaparib in metastatic prostate cancer
  publication-title: N Engl J Med
– volume: 19
  start-page: 664
  year: 2011
  end-page: 678
  ident: bib28
  article-title: Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer
  publication-title: Cancer Cell
– volume: 16
  start-page: 422
  year: 2017
  end-page: 427
  ident: bib36
  article-title: A novel single-cell method provides direct evidence of persistent DNA damage in senescent cells and aged mammalian tissues
  publication-title: Aging Cell
– volume: 103
  start-page: 2352
  year: 2006
  end-page: 2357
  ident: bib44
  article-title: Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma
  publication-title: Proc Natl Acad Sci USA
– volume: 26
  start-page: 2487
  year: 2020
  end-page: 2496
  ident: bib4
  article-title: Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study
  publication-title: Clin Cancer Res
– volume: 35
  start-page: 1014
  year: 2011
  end-page: 1020
  ident: bib24
  article-title: Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas
  publication-title: Am J Surg Pathol
– volume: 20
  start-page: 240
  year: 2019
  end-page: 252
  ident: bib34
  article-title: Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
  publication-title: Genome Biol
– volume: 98
  start-page: 814
  year: 2001
  end-page: 822
  ident: bib45
  article-title: p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation
  publication-title: Blood
– reference: .
– reference: Smith MR, Sandhu SK, Kelly WK, Scher HI, Efstathiou E, Lara P, et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. J Clin Oncol. 2019;37.
– volume: 11
  start-page: 220
  year: 2010
  end-page: 228
  ident: bib43
  article-title: Genomic instability—an evolving hallmark of cancer
  publication-title: Nat Rev Mol Cell Biol
– volume: 16
  start-page: 475
  year: 2014
  end-page: 483
  ident: bib21
  article-title: Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
  publication-title: Breast Cancer Res
– volume: 25
  start-page: 6721
  year: 2019
  end-page: 6730
  ident: bib30
  article-title: Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment naive primary prostate cancer
  publication-title: Clin Cancer Res
– reference: Bono JSD, Mehra N, Higano CS, Saad F, Buttigliero C, Mata M, et al. TALAPRO-1: a phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA). J Clin Oncol. 2020;38.
– volume: 16
  start-page: 1103
  year: 2018
  end-page: 1111
  ident: bib19
  article-title: Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy
  publication-title: Mol Cancer Res
– volume: 38
  start-page: 3763
  year: 2020
  end-page: 3772
  ident: bib7
  article-title: Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration
  publication-title: J Clin Oncol
– volume: 26
  start-page: 2673
  year: 2020
  end-page: 2680
  ident: bib35
  article-title: Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations
  publication-title: Clin Cancer Res
– volume: 32
  start-page: 216
  year: 2020
  end-page: 222
  ident: bib13
  article-title: Therapeutic targeting of the DNA damage response in prostate cancer
  publication-title: Curr Opin Oncol
– volume: 434
  start-page: 917
  year: 2005
  end-page: 921
  ident: bib46
  article-title: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
  publication-title: Nature
– volume: 36
  start-page: 991
  year: 2018
  end-page: 999
  ident: bib29
  article-title: Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012
  publication-title: J Clin Oncol
– volume: 174
  start-page: 758
  year: 2018
  end-page: 769
  ident: bib39
  article-title: Genomic hallmarks and structural variation in metastatic prostate
  publication-title: Cancer Cell
– volume: 119
  start-page: 1060
  year: 2018
  end-page: 1066
  ident: bib20
  article-title: Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
  publication-title: Br J Cancer
– volume: 19
  start-page: 4
  year: 2017
  end-page: 23
  ident: bib22
  article-title: Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
  publication-title: J Mol Diagn
– volume: 375
  start-page: 443
  year: 2016
  end-page: 453
  ident: bib11
  article-title: Inherited DNA-repair gene mutations in men with metastatic prostate cancer
  publication-title: N Engl J Med
– volume: 26
  start-page: 4869
  year: 2020
  end-page: 4881
  ident: bib16
  article-title: Genomic and clinical-pathologic characterization of ATM-deficient prostate cancer
  publication-title: Clin Cancer Res
– volume: 382
  start-page: 2091
  year: 2020
  end-page: 2102
  ident: bib3
  article-title: Olaparib for metastatic castration-resistant prostate cancer
  publication-title: N Engl J Med
– volume: 71
  start-page: 740
  year: 2017
  end-page: 747
  ident: bib14
  article-title: Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death
  publication-title: Eur Urol
– volume: 110
  start-page: 1030
  year: 2018
  end-page: 1034
  ident: bib42
  article-title: The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers
  publication-title: J Natl Cancer Inst
– reference: Antonarakis ES, Wang H, Teply BA, Kelly WK, Willms J, Sullivan R, et al. Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis. J Clin Oncol. 2019;37.
– volume: 23
  start-page: 6863
  year: 2017
  end-page: 6874
  ident: bib26
  article-title: MSH2 loss in primary prostate cancer
  publication-title: Clin Cancer Res
– volume: 38
  start-page: 3735
  year: 2020
  end-page: 3739
  ident: bib41
  article-title: BRCA1 versus BRCA2 and PARP inhibitor sensitivity in prostate cancer: more different than alike?
  publication-title: J Clin Oncol
– reference: PotiAGyergyakHNemethERuszOTothSKovacshaziCCorrelation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agentsGenome Biol2019202405231727117685730510.1186/s13059-019-1867-0
– reference: AbidaWCampbellDPatnaikAShapiroJDSautoisBVogelzangNJNon-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 studyClin Cancer Res2020262487961:CAS:528:DC%2BB3cXitVOgtbvO32086346843535410.1158/1078-0432.CCR-20-0394
– reference: MarkowskiMCAntonarakisESBRCA1 versus BRCA2 and PARP inhibitor sensitivity in prostate cancer: more different than alike?J Clin Oncol2020383735932870734765501810.1200/JCO.20.02246
– reference: KaurHSallesDCMuraliSHicksJLNguyenMPritchardCCGenomic and clinical-pathologic characterization of ATM-deficient prostate cancerClin Cancer Res2020264869811:CAS:528:DC%2BB3cXisFSrtr%2FP32694154750114910.1158/1078-0432.CCR-20-0764
– reference: MarkowskiMCAntonarakisESPARP inhibitors in prostate cancer: time to narrow patient selection?Expert Rev Anticancer Ther20202052361:CAS:528:DC%2BB3cXhsVyjsr%2FN3252117810.1080/14737140.2020.1781622
– reference: PettittARSherringtonPDStewartGCawleyJCTaylorAMStankovicTp53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutationBlood200198814221:CAS:528:DC%2BD3MXlsFKru7s%3D1146818310.1182/blood.V98.3.814
– reference: Antonarakis ES, Wang H, Teply BA, Kelly WK, Willms J, Sullivan R, et al. Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis. J Clin Oncol. 2019;37. https://doi.org/10.1200/JCO.2019.37.15_suppl.5045.
– reference: StronachEAPaulJTimmsKMHughesEBrownKNeffCBiomarker assessment of HR deficiency, tumor BRCA1/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapyMol Cancer Res2018161103111:CAS:528:DC%2BC1cXht1alu77P2972481510.1158/1541-7786.MCR-18-0034
– reference: PatelJNBraicuITimmsKMSolimenoCTshiabaPReidJCharacterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancerBr J Cancer2018119106061:CAS:528:DC%2BC1cXhvFChtrjM30318511621947610.1038/s41416-018-0268-6
– reference: KanchiKLJohnsonKJLuCMcLellanMDLeisersonMDWendlMCIntegrated analysis of germline and somatic variants in ovarian cancerNat Commun201452444849910.1038/ncomms4156
– reference: GuedesLBAntonarakisESSchweizerMTMirkheshtiNAlmutairiFParkJCMSH2 loss in primary prostate cancerClin Cancer Res2017236863741:CAS:528:DC%2BC2sXhvVSnurfM28790115569083410.1158/1078-0432.CCR-17-0955
– reference: MateoJCarreiraSSandhuSMirandaSMossopHPerez-LopezRDNA-repair defects and olaparib in metastatic prostate cancerN Engl J Med201537316977081:CAS:528:DC%2BC28XksVemuro%3D26510020522859510.1056/NEJMoa1506859
– reference: MoraisCLHerawiMToubajiAAlbadineRHicksJNettoGJPTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomasProstate201575161091:CAS:528:DC%2BC2MXhtlelsL7E26178158453735010.1002/pros.23042
– reference: LeonPCancel-TassinGDrouinSAudouinMVarinotJComperatEComparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomyWorld J Urol20183614955001:CAS:528:DC%2BC1cXosFCnsrs%3D2967914010.1007/s00345-018-2290-y
– reference: HussainMDaignault-NewtonSTwardowskiPWAlbanyCSteinMNKunjuLPTargeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012J Clin Oncol20183699191:CAS:528:DC%2BC1cXit1amtr3E2926143910.1200/JCO.2017.75.7310
– reference: WeigeltBBiRKumarRBlecuaPMandelkerDLGeyerFCThe landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriersJ Natl Cancer Inst20181101030429506079613692510.1093/jnci/djy028
– reference: NicolosiPLedetEYangSMichalskiSFreschiBO’LearyEPrevalence of germline variants in prostate cancer and implications for current genetic testing guidelinesJAMA Oncol20195523830730552645911210.1001/jamaoncol.2018.6760
– reference: MarshallCHAntonarakisESTherapeutic targeting of the DNA damage response in prostate cancerCurr Opin Oncol202032216221:CAS:528:DC%2BB3cXmtl2lsLw%3D32168038814765710.1097/CCO.0000000000000617
– reference: FarmerHMcCabeNLordCJTuttANJohnsonDARichardsonTBTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434917211:CAS:528:DC%2BD2MXjtFOmsrc%3D1582996710.1038/nature03445
– reference: JonssonPBandlamudiCChengMLSrinivasanPChavanSSFriedmanNDTumour lineage shapes BRCA-mediated phenotypesNature201957157691:CAS:528:DC%2BC1MXhsVeqs7rN31292550704823910.1038/s41586-019-1382-1
– reference: de BonoJMateoJFizaziKSaadFShoreNSandhuSOlaparib for metastatic castration-resistant prostate cancerN Engl J Med202038220911023234389010.1056/NEJMoa1911440
– reference: SprattDEAlshalalfaMFishbaneNWeinerABMehraRMahalBATranscriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment naive primary prostate cancerClin Cancer Res2019256721301:CAS:528:DC%2BB3cXhslWitL7F31515456685896410.1158/1078-0432.CCR-19-1587
– reference: BrennerJCAteeqBLiYYocumAKCaoQAsanganiIAMechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancerCancer Cell201119664781:CAS:528:DC%2BC3MXmtFGlsL4%3D21575865311347310.1016/j.ccr.2011.04.010
– reference: PolakPKimJBraunsteinLZKarlicRHaradhavalaNJTiaoGA mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancerNat Genet2017491476861:CAS:528:DC%2BC2sXhtlKjtbvL28825726737675110.1038/ng.3934
– reference: MarshallCHSokolovaAOMcNattyALChengHHEisenbergerMABryceAHDifferential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutationsEur Urol20197645281:CAS:528:DC%2BC1MXjtVWitr4%3D30797618670397410.1016/j.eururo.2019.02.002
– reference: HughleyRKarlicRJoshiHTurnbullCFoulkesWDPolakPEtiologic index: a case-only measure of BRCA1/2-associated cancer riskN Engl J Med2020383286832668122754637010.1056/NEJMc1913988
– reference: LiMMDattoMDuncavageEJKulkarniSLindemanNIRoySStandards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American PathologistsJ Mol Diagn2017194231:CAS:528:DC%2BC28XitFWls7jM27993330570719610.1016/j.jmoldx.2016.10.002
– reference: NaRZhengSLHanMYuHJiangDShahSGermline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at deathEur Urol20177174071:CAS:528:DC%2BC28XhvF2mtLnO2798935410.1016/j.eururo.2016.11.033
– reference: GreinerTCDasguptaCHoVVWeisenburgerDDSmithLMLynchJCMutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphomaProc Natl Acad Sci USA2006103235271:CAS:528:DC%2BD28XhslGjt7w%3D16461462141371610.1073/pnas.0510441103
– reference: PritchardCCMateoJWalshMFDe SarkarNAbidaWBeltranHInherited DNA-repair gene mutations in men with metastatic prostate cancerN Engl J Med2016375443531:CAS:528:DC%2BC28XhvF2ks7%2FN27433846498661610.1056/NEJMoa1603144
– reference: LalondeEIshkanianASSykesJFraserMRoss-AdamsHErhoNTumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort studyLancet Oncol2014151521322545637110.1016/S1470-2045(14)71021-6
– reference: GuidugliLCarreiraACaputoSMEhlenAGalliAMonteiroANFunctional assays for analysis of variants of uncertain significance in BRCA2Hum Mutat201435151641:CAS:528:DC%2BC2cXotFWmtg%3D%3D2432393810.1002/humu.22478
– reference: NegriniSGorgoulisVGHalazonetisTDGenomic instability—an evolving hallmark of cancerNat Rev Mol Cell Biol20101122081:CAS:528:DC%2BC3cXitlaisb4%3D2017739710.1038/nrm2858
– reference: ChauxAAlbadineRToubajiAHicksJMeekerAPlatzEAImmunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomasAm J Surg Pathol20113510142021677539350567610.1097/PAS.0b013e31821e8761
– reference: Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis Oncol. 2019;3. https://doi.org/10.1200/PO.18.00283.
– reference: AbidaWPatnaikACampbellDShapiroJBryceAHMcDermottRRucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alterationJ Clin Oncol2020383763721:CAS:528:DC%2BB3cXisVKls7nP32795228765502110.1200/JCO.20.01035
– reference: QuigleyDADangHXZhaoSGLloydPAggarwalRAlumkalJJGenomic hallmarks and structural variation in metastatic prostateCancer Cell2018174758691:CAS:528:DC%2BC1cXhtlGltb%2FE
– reference: Bono JSD, Mehra N, Higano CS, Saad F, Buttigliero C, Mata M, et al. TALAPRO-1: a phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA). J Clin Oncol. 2020;38. https://doi.org/10.1200/JCO.2020.38.6_suppl.119.
– reference: Velho PI, Lim D, Wang H, Park JC, Kaur HB, Almutairi F, et al. Molecular characterization and clinical outcomes of primary gleason pattern 5 prostate cancer after radical prostatectomy. JCO Precis Oncol. 2019;3. https://doi.org/10.1200/PO.19.00081.
– reference: Smith MR, Sandhu SK, Kelly WK, Scher HI, Efstathiou E, Lara P, et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. J Clin Oncol. 2019;37. https://doi.org/10.1200/JCO.2019.37.7_suppl.202.
– reference: TelliMLTimmsKMReidJHennessyBMillsGBJensenKCHomologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancerClin Cancer Res2016223764731:CAS:528:DC%2BC28Xht1yhtbrM26957554677342710.1158/1078-0432.CCR-15-2477
– reference: PomerantzMMSpisakSJiaLCroninAMCsabaiILedetEThe association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancerCancer2017123353291:CAS:528:DC%2BC2sXhsVGhsrnF2860893110.1002/cncr.30808
– reference: SztupinszkiZDiossyMKrzystanekMBorcsokJPomerantzMMTiszaVDetection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutationsClin Cancer Res2020262673801:CAS:528:DC%2BB3cXitVKrt7jK32071115838708610.1158/1078-0432.CCR-19-2135
– reference: TimmsKMAbkevichVHughesENeffCReidJMorrisBAssociation of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypesBreast Cancer Res2014164758325475740430891010.1186/s13058-014-0475-x
– reference: GalbiatiABeausejourCd’Addadi FagagnaFA novel single-cell method provides direct evidence of persistent DNA damage in senescent cells and aged mammalian tissuesAging Cell20171642271:CAS:528:DC%2BC2sXhs1WgsLY%3D28124509533454210.1111/acel.12573
– reference: Cancer Genome Atlas Research N.The molecular taxonomy of primary prostate cancerCell201516310112510.1016/j.cell.2015.10.025
– reference: LheureuxSLaiZDoughertyBARunswickSHodgsonDRTimmsKMLong-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterizationClin Cancer Res2017234086941:CAS:528:DC%2BC2sXht1Ghu7fJ2822327410.1158/1078-0432.CCR-16-2615
– volume: 71
  start-page: 740
  year: 2017
  ident: 10.1038/s41379-020-00731-4_bib14
  article-title: Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2016.11.033
– volume: 163
  start-page: 1011
  year: 2015
  ident: 10.1038/s41379-020-00731-4_bib17
  article-title: The molecular taxonomy of primary prostate cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2015.10.025
– volume: 16
  start-page: 475
  year: 2014
  ident: 10.1038/s41379-020-00731-4_bib21
  article-title: Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-014-0475-x
– volume: 19
  start-page: 664
  year: 2011
  ident: 10.1038/s41379-020-00731-4_bib28
  article-title: Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.04.010
– volume: 35
  start-page: 1014
  year: 2011
  ident: 10.1038/s41379-020-00731-4_bib24
  article-title: Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0b013e31821e8761
– volume: 26
  start-page: 2487
  year: 2020
  ident: 10.1038/s41379-020-00731-4_bib4
  article-title: Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-0394
– volume: 383
  start-page: 286
  year: 2020
  ident: 10.1038/s41379-020-00731-4_bib33
  article-title: Etiologic index: a case-only measure of BRCA1/2-associated cancer risk
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc1913988
– volume: 38
  start-page: 3763
  year: 2020
  ident: 10.1038/s41379-020-00731-4_bib7
  article-title: Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.20.01035
– volume: 22
  start-page: 3764
  year: 2016
  ident: 10.1038/s41379-020-00731-4_bib10
  article-title: Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-2477
– volume: 103
  start-page: 2352
  year: 2006
  ident: 10.1038/s41379-020-00731-4_bib44
  article-title: Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0510441103
– volume: 75
  start-page: 1610
  year: 2015
  ident: 10.1038/s41379-020-00731-4_bib23
  article-title: PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas
  publication-title: Prostate
  doi: 10.1002/pros.23042
– volume: 123
  start-page: 3532
  year: 2017
  ident: 10.1038/s41379-020-00731-4_bib38
  article-title: The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer
  publication-title: Cancer
  doi: 10.1002/cncr.30808
– volume: 373
  start-page: 1697
  year: 2015
  ident: 10.1038/s41379-020-00731-4_bib2
  article-title: DNA-repair defects and olaparib in metastatic prostate cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1506859
– volume: 38
  start-page: 3735
  year: 2020
  ident: 10.1038/s41379-020-00731-4_bib41
  article-title: BRCA1 versus BRCA2 and PARP inhibitor sensitivity in prostate cancer: more different than alike?
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.20.02246
– volume: 119
  start-page: 1060
  year: 2018
  ident: 10.1038/s41379-020-00731-4_bib20
  article-title: Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
  publication-title: Br J Cancer
  doi: 10.1038/s41416-018-0268-6
– volume: 26
  start-page: 2673
  year: 2020
  ident: 10.1038/s41379-020-00731-4_bib35
  article-title: Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-2135
– volume: 5
  start-page: 523
  year: 2019
  ident: 10.1038/s41379-020-00731-4_bib12
  article-title: Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2018.6760
– ident: 10.1038/s41379-020-00731-4_bib1
  doi: 10.1200/PO.18.00283
– volume: 49
  start-page: 1476
  year: 2017
  ident: 10.1038/s41379-020-00731-4_bib32
  article-title: A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
  publication-title: Nat Genet
  doi: 10.1038/ng.3934
– volume: 76
  start-page: 452
  year: 2019
  ident: 10.1038/s41379-020-00731-4_bib8
  article-title: Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2019.02.002
– volume: 35
  start-page: 151
  year: 2014
  ident: 10.1038/s41379-020-00731-4_bib37
  article-title: Functional assays for analysis of variants of uncertain significance in BRCA2
  publication-title: Hum Mutat
  doi: 10.1002/humu.22478
– volume: 16
  start-page: 1103
  year: 2018
  ident: 10.1038/s41379-020-00731-4_bib19
  article-title: Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-18-0034
– volume: 36
  start-page: 991
  year: 2018
  ident: 10.1038/s41379-020-00731-4_bib29
  article-title: Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.75.7310
– volume: 174
  start-page: 758
  year: 2018
  ident: 10.1038/s41379-020-00731-4_bib39
  article-title: Genomic hallmarks and structural variation in metastatic prostate
  publication-title: Cancer Cell
– volume: 20
  start-page: 523
  year: 2020
  ident: 10.1038/s41379-020-00731-4_bib47
  article-title: PARP inhibitors in prostate cancer: time to narrow patient selection?
  publication-title: Expert Rev Anticancer Ther
  doi: 10.1080/14737140.2020.1781622
– volume: 375
  start-page: 443
  year: 2016
  ident: 10.1038/s41379-020-00731-4_bib11
  article-title: Inherited DNA-repair gene mutations in men with metastatic prostate cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1603144
– volume: 19
  start-page: 4
  year: 2017
  ident: 10.1038/s41379-020-00731-4_bib22
  article-title: Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
  publication-title: J Mol Diagn
  doi: 10.1016/j.jmoldx.2016.10.002
– ident: 10.1038/s41379-020-00731-4_bib5
  doi: 10.1200/JCO.2019.37.7_suppl.202
– volume: 16
  start-page: 422
  year: 2017
  ident: 10.1038/s41379-020-00731-4_bib36
  article-title: A novel single-cell method provides direct evidence of persistent DNA damage in senescent cells and aged mammalian tissues
  publication-title: Aging Cell
  doi: 10.1111/acel.12573
– volume: 23
  start-page: 4086
  year: 2017
  ident: 10.1038/s41379-020-00731-4_bib40
  article-title: Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-16-2615
– volume: 26
  start-page: 4869
  year: 2020
  ident: 10.1038/s41379-020-00731-4_bib16
  article-title: Genomic and clinical-pathologic characterization of ATM-deficient prostate cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-0764
– volume: 98
  start-page: 814
  year: 2001
  ident: 10.1038/s41379-020-00731-4_bib45
  article-title: p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation
  publication-title: Blood
  doi: 10.1182/blood.V98.3.814
– volume: 20
  start-page: 240
  year: 2019
  ident: 10.1038/s41379-020-00731-4_bib34
  article-title: Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
  publication-title: Genome Biol
  doi: 10.1186/s13059-019-1867-0
– volume: 23
  start-page: 6863
  year: 2017
  ident: 10.1038/s41379-020-00731-4_bib26
  article-title: MSH2 loss in primary prostate cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-0955
– volume: 32
  start-page: 216
  year: 2020
  ident: 10.1038/s41379-020-00731-4_bib13
  article-title: Therapeutic targeting of the DNA damage response in prostate cancer
  publication-title: Curr Opin Oncol
  doi: 10.1097/CCO.0000000000000617
– volume: 5
  year: 2014
  ident: 10.1038/s41379-020-00731-4_bib25
  article-title: Integrated analysis of germline and somatic variants in ovarian cancer
  publication-title: Nat Commun
  doi: 10.1038/ncomms4156
– volume: 36
  start-page: 1495
  year: 2018
  ident: 10.1038/s41379-020-00731-4_bib18
  article-title: Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy
  publication-title: World J Urol
  doi: 10.1007/s00345-018-2290-y
– volume: 434
  start-page: 917
  year: 2005
  ident: 10.1038/s41379-020-00731-4_bib46
  article-title: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
  publication-title: Nature
  doi: 10.1038/nature03445
– ident: 10.1038/s41379-020-00731-4_bib6
  doi: 10.1200/JCO.2020.38.6_suppl.119
– volume: 382
  start-page: 2091
  year: 2020
  ident: 10.1038/s41379-020-00731-4_bib3
  article-title: Olaparib for metastatic castration-resistant prostate cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1911440
– volume: 110
  start-page: 1030
  year: 2018
  ident: 10.1038/s41379-020-00731-4_bib42
  article-title: The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djy028
– ident: 10.1038/s41379-020-00731-4_bib15
  doi: 10.1200/PO.19.00081
– volume: 15
  start-page: 1521
  year: 2014
  ident: 10.1038/s41379-020-00731-4_bib27
  article-title: Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)71021-6
– volume: 11
  start-page: 220
  year: 2010
  ident: 10.1038/s41379-020-00731-4_bib43
  article-title: Genomic instability—an evolving hallmark of cancer
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm2858
– ident: 10.1038/s41379-020-00731-4_bib9
  doi: 10.1200/JCO.2019.37.15_suppl.5045
– volume: 25
  start-page: 6721
  year: 2019
  ident: 10.1038/s41379-020-00731-4_bib30
  article-title: Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment naive primary prostate cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-1587
– volume: 571
  start-page: 576
  year: 2019
  ident: 10.1038/s41379-020-00731-4_bib31
  article-title: Tumour lineage shapes BRCA-mediated phenotypes
  publication-title: Nature
  doi: 10.1038/s41586-019-1382-1
SSID ssj0014582
Score 2.5849335
Snippet The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer....
SourceID pubmedcentral
proquest
pubmed
crossref
springer
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1185
SubjectTerms 45
631/67/1857
631/67/589/466
Adult
Aged
Allelic Imbalance - genetics
Ataxia Telangiectasia Mutated Proteins - genetics
Biomarkers, Tumor - genetics
BRCA1 protein
BRCA2 protein
BRCA2 Protein - genetics
FDA approval
Genomic instability
Genomic Instability - genetics
Germ-Line Mutation - genetics
Heterozygosity
Homologous recombination
Humans
Laboratory Medicine
Loss of Heterozygosity - genetics
Male
Medicine
Medicine & Public Health
Middle Aged
Mutation
Ovarian cancer
Ovarian carcinoma
p53 Protein
Pathology
Poly(ADP-ribose) polymerase
Prostate cancer
Prostatic Neoplasms - genetics
Tumors
Title Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
URI https://dx.doi.org/10.1038/s41379-020-00731-4
https://link.springer.com/article/10.1038/s41379-020-00731-4
https://www.ncbi.nlm.nih.gov/pubmed/33462368
https://www.proquest.com/docview/2530776125
https://www.proquest.com/docview/2479038753
https://pubmed.ncbi.nlm.nih.gov/PMC8154637
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BK1AvCMqjoaUyEgcQWN3YzsMntH1pAW2FVq20NytxHFGpm912lwP_vjOOk6pU3WMeTuLMeOYbzwvgk7aidnUpeK2E5UoNLMrB2nG0NQSqZ-VKSwnO47N0dKF-TpNp2HBbhrDKTiZ6QV3NLe2RH4hEUuUZ1MffF9ecukaRdzW00HgKmzEiEWrdkE17gysmn5BHkVpyqRMRkmYGMj9YovDONCfjiZxVaEc9ppgeAs-H8ZP_OVG9bjp9CS8CqGTDlgtewRPXbMOzts3kv214Pg4O9NfgRvMZnUV7n5EtPEPD2NOGVY5qSVAiJvs8mhx_YUsqcMkuG4YvnBEYZYeTo6HgjAI5cPjwfMy9r91VbEG5I4hamSUmunkDF6cn50cjHjotcJtoueJ5UcdOp07jnNKsklVpM1cPYqtrIbTKiM6ZKkuhHErWalBqi7BSJ1WK4_Mkl29ho5k3bodywGVRWils4hAcWJXHhVN1rmRh8VFVGUHc_WZjQxly6oZxZbw7XOamJY1B0hhPGqMi-NqPWbRFONbenXTUMwFGtPDAoJZYO26vI7UJC3lp7tgugo_9ZVyC5FcpGofkMkJlmqIAEhnBu5Yz-s-UUiHATPMIsns8099A5b3vX2ku__gy33lMrQqyCL513HX3WY_P4v36WezClqCoHL-PtAcbq5u_7gPCqlW579fOPmwenpz9nuDR8Y9ft-dtHwo
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTjBeEAwYgQFGAgkE1hrbaeKHCXVfythaoaqT9mYSxxGTaFqWTmj_HH8bd_noNKb1ba-JncS5893vfF8A77UVuctTwXMlLFeqa1EO5o6jrSFQPSuXWkpwHgx78Yn6dhqcrsDfNheGwipbmVgJ6mxq6Yx8SwSSKs-gPv46-82paxR5V9sWGknTWiHbrkqMNYkdR-7yD5pw5fbhHtL7gxAH--PdmDddBrgNtJzzKMl9p3tOu8z2wkxmqQ1d3vWtzoXQKqQ1hipNhXIoVbJuqi1CKh1kPZwfBZHE596DVUUHKB1Y3dkffh8t_BjklapwrJZc6kA0aTtdGW2VqD5Czcl8I3cZWnK3qcab0PdmBOd_btxKOx48hkcNrGX9mg-fwIor1uF-3ejych0eDBoX_lNw8XRCV6cXJSNrfIKmecUdLHNUzYJSQdnHeLT3iZVUYpOdFQxfOCE4zHZGu33BGYWS4PT-eMArb7_L2IyyVxA3M0tsfP4MTu6ECs-hU0wL94Ky0GWSWils4BCeWBX5iVN5pGRi8VFZ6oHf_mZjm0Lo1I_jl6kc8jIyNWkMksZUpDHKg8-LObO6DMjS0UFLPdMAmRqgGNRTS-dttqQ2jSgpzRXje_BucRuFAHl2ksIhuYxQoaY4hEB6sFFzxuIzpVQIcXuRB-E1nlkMoALj1-8UZz-rQuORT80SQg--tNx19Vm3r-Ll8lW8hbV4PDg2x4fDo1fwUFCMUHWqtQmd-fmFe40gb56-aXYSgx93vXn_AefQYSs
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTUy8IBhfgQFGAgkEVhvbaeKHCXXrqo7Raqo2aW8mcRwxiaZl7YT2L_JXcZc4nca0vu01sZ04d777Xe4L4L22onBFJnihhOVKtS3KwcJxtDUEqmflMksJzsNRZ3Civp1Gp2vwt8mFobDKRiZWgjqfWvpH3hKRpMozqI9bhQ-LOOr1v85-c-ogRZ7Wpp1G6tss5DtVuTGf5HHoLv-gOTffOegh7T8I0d8_3htw33GA20jLBU_SInS647TLbSfOZZ7Z2BXt0OpCCK1i2m-sskwohxImb2faIrzSUd7B-UmUSFz3HmzEqPXRENzY3R8djZc-DfJQVZhWSy51JHwKT1smrTmqklhzMuXIdYZW3W1q8iYMvhnN-Z9Lt9KU_Ufw0ENc1q158jGsuXIL7tdNLy-3YHPo3flPwA2mE7o6vZgzsswnaKZXnMJyR5UtKC2UfRyMe5_YnMptsrOS4QMnBI3Z7nivKzijsBKc3j0e8srz73I2o0wWxNDMEkufP4WTO6HCM1gvp6V7QRnpMs2sFDZyCFWsSsLUqSJRMrW4VJ4FEDaf2VhfFJ16c_wylXNeJqYmjUHSmIo0RgXweTlnVpcEWTk6aqhnPKipwYpBnbVy3nZDauPFytxcHYIA3i1vo0AgL09aOiSXESrWFJMQyQCe15yxfE0pFcLdThJAfI1nlgOo2Pj1O-XZz6roeBJS44Q4gC8Nd1291u27eLl6F29hEw-x-X4wOnwFDwSFC1U_uLZhfXF-4V4j3ltkb_xBYvDjrs_uP82hZW8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Homologous+recombination+deficiency+%28HRD%29+score+in+germline+BRCA2-+versus+ATM-altered+prostate+cancer&rft.jtitle=Modern+pathology&rft.au=Lotan%2C+Tamara+L&rft.au=Kaur%2C+Harsimar+B&rft.au=Salles%2C+Daniela+C&rft.au=Murali%2C+Sanjana&rft.date=2021-06-01&rft.eissn=1530-0285&rft.volume=34&rft.issue=6&rft.spage=1185&rft_id=info:doi/10.1038%2Fs41379-020-00731-4&rft_id=info%3Apmid%2F33462368&rft.externalDocID=33462368
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-3952&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-3952&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-3952&client=summon